Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-070378
Filing Date
2025-05-13
Accepted
2025-05-13 16:15:35
Documents
80
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q lctx-20250331.htm   iXBRL 10-Q 2181109
2 EX-31.1 lctx-ex31_1.htm EX-31.1 16499
3 EX-31.2 lctx-ex31_2.htm EX-31.2 14659
4 EX-32.1 lctx-ex32_1.htm EX-32.1 13705
  Complete submission text file 0000950170-25-070378.txt   10671381

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lctx-20250331.xsd EX-101.SCH 1807434
83 EXTRACTED XBRL INSTANCE DOCUMENT lctx-20250331_htm.xml XML 1883517
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12830 | Film No.: 25940327
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)